🔎 Trials Near Me

Home › Chronic Progressive Multiple Sclerosis

Pag-aaral pangklinika para sa Chronic Progressive Multiple Sclerosis na nagre-recruit sa U.S.

18 pag-aaral para sa Chronic Progressive Multiple Sclerosis ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.

Mga lungsod na may pinakamaraming pag-aaral

Ayos sa estado

Mga pag-aaral na kamakailan lamang in-update

Opisyal na teksto ng pag-aaral (English)

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

Nagre-recruitPhase 2
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07840326

A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Nagre-recruitPhase 3
Edad 18 hanggang 60 · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07299019

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

Nagre-recruitPhase 3
Edad 18 hanggang 60 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07067463

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

Nagre-recruitPhase 1/2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07477639

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Nagre-recruitPhase 3
Edad 18 hanggang 55 · Lahat ng kasarian · Na-update Set 16, 2026 · NCT04047628

A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

Nagre-recruitPhase 4
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT07609719

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Nagre-recruitPhase 1/2
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Ago 27, 2026 · NCT03109288

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Nagre-recruitPhase 3
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT07225504

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Nagre-recruitPhase 1/2
Edad 18 hanggang 55 · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05359653

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

Nagre-recruitPhase 1
Edad 18 hanggang 60 · Lahat ng kasarian · Na-update Mar 23, 2026 · NCT07139743

Intermittent Hypoxia in Persons With Multiple Sclerosis

Nagre-recruit
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Mar 20, 2026 · NCT06276634

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Nagre-recruitPhase 1
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Peb 27, 2026 · NCT06138132

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

Nagre-recruit
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Peb 23, 2026 · NCT06390930

Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients

Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 12, 2026 · NCT07392879

Home Based Functional Balance Intervention for Multiple Sclerosis

Nagre-recruit
Edad 40 hanggang 90 · Lahat ng kasarian · Na-update Ene 21, 2026 · NCT07355387

"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS

Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 31, 2025 · NCT07222618

Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis

Nagre-recruit
Edad 22 hanggang 75 · Lahat ng kasarian · Na-update Set 24, 2025 · NCT05964829

MS-ResearchBiomarkerS

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryoMay bayad para sa mga kalahok
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 6, 2024 · NCT05204459

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.